Identification of a Novel Risk Model: A Five-Gene Prognostic Signature for Pancreatic Cancer.

OBJECTIVE

Biomarkers for pancreatic cancer (PCa) prognosis provide evidence for improving the survival outcome of this disease. This study aimed to identify a prognostic risk model based on gene expression profiling of microarray bioinformatics analysis.

METHODS

Prognostic immune genes in the TCGA-PAAD cohort were identified using the univariate Cox regression and Kaplan-Meier survival analysis. Multivariate Cox regression (stepAIC) was used to identify prognostic genes from the top 20 hub genes in the protein-protein interaction (PPI) network. A prognostic risk model was established and its performance in predicting the overall survival in PCa was validated in GSE62452. Gene mutations and infiltration immune cells in PCa tumors were analyzed using online databases.

RESULTS

Univariate Cox regression and Kaplan-Meier survival analyses identified 128 prognostic genes. Multivariate Cox regression (stepAIC) identified five prognostic genes (PLCG1, MET, TNFSF10, CXCL9, and TLR3) out of the 20 hub genes in the PPI network. A prognostic risk model was established using the signature of five genes. This model had moderate to high accuracies (AUC > 0.700) in predicting 3-year and 5-year overall survival in TCGA and GSE62452 cohorts. The Kaplan-Meier survival analysis showed that high-risk scores were correlated with poor survival outcomes in PCa ( < 0.05). Also, mutations in the five genes were related to poor survival. The five genes were related to multiple immune cells.

CONCLUSIONS

The prognostic risk model was significantly correlated with the survival in PCa patients. This model modulated PCa tumor progression and prognosis by regulating immune cell infiltration.